13/09/2022 (Agence Europe) – The European Commission granted conditional marketing authorisation for a new adapted SARS-CoV-2 vaccine on Monday 12 September. This follows the recommendation published the same day by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) (see EUROPE 13019/12) in favour of authorising this vaccine. This bivalent messenger RNA vaccine developed by Pfizer-BioNTech targets the BA.4 and BA.5 sub-variants of concern of SARS-CoV-2 as well as its original strain (see EUROPE 13012/23). The administration of this ‘Comirnaty’ vaccine is recommended for adults aged 12 years and older who have already completed a first vaccination course against SARS-CoV-2. A Pfizer-BioNTech vaccine and a Moderna vaccine adapted to the original SARS-CoV-2 strain and the BA.1 sub-variant were already licenced on 1 September (see EUROPE 13013/14). (EV)